Monitoring futility and efficacy in phase II trials with Bayesian posterior distributions—A calibration approach-Reference-Cited by-同舟云学术

Monitoring futility and efficacy in phase II trials with Bayesian posterior distributions—A calibration approach

Published:2018-09-02 Issue:3 Volume:61 Page:488-502
ISSN:0323-3847
Container-title:Biometrical Journal
language:en
Short-container-title:Biom. J.

Author:

Kopp‐Schneider Annette¹^ORCID,Wiesenfarth Manuel¹,Witt Ruth²³,Edelmann Dominic¹,Witt Olaf³,Abel Ulrich²

Affiliation:

1. Division of BiostatisticsGerman Cancer Research Center (DKFZ)Heidelberg Germany

2. Clinical Trial CenterNational Center for Tumor DiseasesHeidelberg Germany

3. Hopp Children's Cancer Center at NCT Heidelberg (KiTZ), Department of Pediatric Oncology and Hematology and Clinical Cooperation Unit Pediatric OncologyUniversity Hospital and German Cancer Research Center (DKFZ)Heidelberg Germany

Funder

National Center for Tumor Diseases

Publisher

Wiley

Subject

Statistics, Probability and Uncertainty,General Medicine,Statistics and Probability

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/bimj.201700209

Reference18 articles.

1. Patients in Pediatric Phase I and Early Phase II Clinical Oncology Trials at Gustave Roussy

2. Bayesian hierarchical modeling of patient subpopulations: Efficient designs of Phase II oncology clinical trials

3. [DLMF] NIST Digital Library of Mathematical Functions. http://dlmf.nist.gov/ Release1.0.16 of2017‐09‐18.Olver F. W. J. Olde DaalhuisA. B. LozierD. W. SchneiderB. I. BoisvertR. F. ClarkC. W. MillerB. R. andSaundersB. V. eds.

4. An optimal three-stage design for phase II clinical trials

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Robust incorporation of historical information with known type I error rate inflation;Biometrical Journal;2023-12-08

2. BayesCTDesign: An R Package for Bayesian Trial Design Using Historical Control Data;Journal of Statistical Software;2021

3. INFORM2 NivEnt: The first trial of the INFORM2 biomarker driven phase I/II trial series: the combination of nivolumab and entinostat in children and adolescents with refractory high-risk malignancies;BMC Cancer;2020-06-05

4. Power gains by using external information in clinical trials are typically not possible when requiring strict type I error control;Biometrical Journal;2019-07-02

5. BDP2: Bayesian Adaptive Designs for Phase II Trials with Binary Endpoint;CRAN: Contributed Packages;2018-07-31